We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+27.41%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$2.58B
AUM Growth
-$40.8M
Cap. Flow
-$216M
Cap. Flow %
-8.36%
Top 10 Hldgs %
47.96%
Holding
78
New
7
Increased
10
Reduced
27
Closed
8

Top Buys

Rank Stock Value
1
SYK icon
Stryker
SYK
+$33.1M
2
VTYX
Ventyx Biosciences
VTYX
+$30.2M
3
PEN icon
Penumbra
PEN
+$28.7M
4
PLRX icon
Pliant Therapeutics
PLRX
+$27.5M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$26.3M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$151M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$72.8M
3
ARGX icon
argenx
ARGX
+$39.2M
4
SKIN icon
SkinHealth Systems
SKIN
+$38.9M
5
CNC icon
Centene
CNC
+$33M

Sector Composition

Rank Sector Weight
1 Healthcare 98.01%
2 Consumer Staples 0.96%
3 Industrials 0.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
76
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-854,013
Closed -$151M
AYLA
77
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
– –
-341,030
Closed -$372K
HZNP
78
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-913,319
Closed -$72.8M
1 2 3
4

Similar funds

KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Redmile Group's Q3 2022 Portfolio in Review

As of Q3 2022, Redmile Group held 78 positions worth $2.58B, down 1.6% from $2.62B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Redmile Group withdrew a net $216M in Q3 2022, closing 8 positions and reducing 27 holdings. Its most notable exit was Seagen Inc. Common Stock, an estimated $151M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Redmile Group opened a new position in Stryker worth $31.9M.

  • Redmile Group's largest Q3 2022 buy was Stryker: 157,321 shares worth $31.9M.
  • Redmile Group added most to Pliant Therapeutics in Q3 2022, an estimated $27.5M increase.
  • Redmile Group's biggest Q3 2022 reduction was argenx, cutting an estimated $39.2M.
  • Redmile Group fully exited Seagen Inc. Common Stock in Q3 2022, selling an estimated $151M.
  • Redmile Group's ten largest holdings make up 48% of its $2.58B portfolio in Q3 2022.
  • Redmile Group opened 7 new positions and closed 8 in Q3 2022.
  • Redmile Group's portfolio value fell 1.6% quarter-over-quarter to $2.58B.

Based on Redmile Group's 13F filing for Q3 2022, filed 14 Nov 2022.